Can Myriad Genetics (MYGN) Stock Reach $8?

Key Takeaways

• The central $8 target is a single, publicly discussed price objective from Craig-Hallum, not a consensus figure; the average of current analyst targets is near $4, below the share price.
• Shares traded near $5.70 in October 2026 after Myriad announced the sale of its prenatal health testing business to Labcorp, up from a $4.21 prior close.
• Reaching $8 would require roughly 40% upside from recent levels, a very large move.
• The analyst range is unusually wide, from $2 (Piper Sandler) to $8 (Craig-Hallum), reflecting deep disagreement about the company's direction.
• Key supports include the prenatal divestiture's expected boost to growth and margins; key risks include repeated guidance cuts and weak prenatal testing volumes.

How the $8 Target Was Established

Myriad Genetics, Inc. (MYGN) is a Salt Lake City-based molecular diagnostics and precision-medicine company known for hereditary cancer, oncology, and pharmacogenomics tests. Because most current analyst targets sit at or below the recent share price, an analyst-derived central target was not usable under the 10% minimum-distance test. The $8 figure therefore comes from public discussion rather than a consensus: it is the price objective set by Craig-Hallum analyst John Wilkin, who on October 2, 2026 raised the firm's target from $4 to $8 while maintaining a Buy rating.

For context, the verified individual targets reviewed span a wide range — Piper Sandler at $2, Wells Fargo and Stephens at $3, UBS at $3.60, Bank of America at $4, TD Cowen at $4.50, and Craig-Hallum at $8 — producing a mean near $4.00, consistent with MarketBeat's independently reported average of $4.02. The gap between that sub-$4 consensus and the $8 objective underscores how divergent views on Myriad have become.

Current Market Position and Path Toward the Target

Following the October 2026 announcement that Myriad will sell its Prenatal Health testing business to Labcorp Holdings Inc. (LH) for $210 million in cash plus inventory value, shares surged roughly 35% to trade near $5.70, from a $4.21 prior close. Reaching $8 would require an additional gain of about 40%, a very large move for a company that has spent the past year resetting expectations.

The path is complicated by a weak fundamental backdrop. In its second-quarter 2026 report, Myriad lowered full-year revenue guidance to $770 million–$790 million from $860 million–$880 million, citing lower prenatal testing volumes, while quarterly revenue of $190.7 million fell short of estimates and the company posted a larger-than-expected adjusted loss. The divestiture removes a declining segment and bolsters the balance sheet, but it also removes a meaningful revenue stream the company must replace with growth in its core oncology and diagnostics franchise.

What Could Support a Move Toward the Target

• The prenatal sale is expected to be accretive to revenue growth and gross margin, and Craig-Hallum cited the divestiture as a primary catalyst for its $8 target.
• Approximately $210 million in cash, roughly half of the company's pre-announcement market capitalization, materially strengthens the balance sheet and could fund strategic reinvestment.
• Core offerings such as hereditary cancer risk testing and pharmacogenomics retain large addressable markets and established reimbursement relationships.
• If management maintains or slightly exceeds third-quarter guidance on the November 4, 2026 call, sentiment could improve quickly given how depressed expectations have become.

What Could Prevent the Target From Being Reached

• Sell-side sentiment remains cautious: most recent targets sit at or below the share price, with Piper Sandler's downgrade to Underweight and a $2 target reflecting deep concern.
• Prenatal testing revenue declined 16% year over year in the second quarter, contributing to a guidance cut and persistent uncertainty about volume and reimbursement trends.
• The company is not yet consistently profitable, and traditional valuation tools such as the P/E (price-to-earnings) ratio are not useful while earnings are negative.
• Competition in genetic testing is intense, and losing the prenatal portfolio removes a product line that, while declining, still contributed meaningful volume and clinician relationships.

Technical Levels and Market Structure

Technically, the shares have been volatile, with a 52-week range of $2.74 to $8.50 and a beta near 1.64. The $8 objective sits just below the November 2025 52-week high of $8.50, an area that could act as overhead resistance. The stock's 50-day and 200-day moving averages, near $3.68 and $4.36 respectively, remain well below current levels, indicating the recent rally has moved shares far above their longer-term trend — a structure that can support momentum but also leaves limited nearby support if sentiment reverses.

Time Horizon and What Investors Should Monitor

Individual price objectives typically reflect a roughly 12-month research horizon, though Craig-Hallum framed its $8 target in the context of the next several quarters of execution. Investors should watch the November 4, 2026 third-quarter results and guidance, any update on the Labcorp transaction's expected close in early 2027, analyst target revisions after the divestiture, and whether core oncology and diagnostics volumes can offset the loss of prenatal revenue. Balance-sheet deployment of the sale proceeds will also be a key signal.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, heavily debated name like Myriad Genetics, traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening allows. Explore the AI Daily Buy/Sell Signals to see how AI-driven monitoring can support your own decision-making process.

Final Assessment

Whether Myriad Genetics can reach $8 depends on whether the prenatal divestiture genuinely transforms the company's growth and margin profile, as Craig-Hallum's publicly discussed target assumes. The required move of roughly 40% is very large, and it runs against a cautious sell-side backdrop in which the average target is near $4 and several analysts hold prices below the current share price. The strengthened balance sheet and a cleaner focus on higher-growth diagnostics are real supports, but repeated guidance cuts, negative earnings, and unresolved volume trends are substantial obstacles. The wide $2-to-$8 range of analyst views reflects genuine uncertainty, and investors should weigh the upcoming earnings update and transaction details carefully rather than treating any single objective as a forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations